The class of medication – known as calcitonin gene-related peptide (CGRP) monoclonal antibodies – are injections that have been shown to prevent the condition in 50 per cent of patients

An innovative ‘wonder’ drug used to treat migraines on the NHS may cause miscarriages, concerning new research has warned.

The class of medication – known as calcitonin gene-related peptide (CGRP) monoclonal antibodies – are injections that have been shown to prevent the condition in 50 per cent of patients.

However, the latest study presented at the American Headache Society (AHS) Annual Meeting, in Florida, found that when used in early pregnancy the drugs increase the risk of miscarriage by 45 per cent.

The study analysed data from 7579 pregnancies in 7119 women aged 15-45 years who had a migraine diagnosis before pregnancy.

The researchers compared three groups, patients on CGRP monoclonal antibody injections, those on the beta-blocker propranolol and those not taking medication.

They found that miscarriages increased among those taking CGRP monoclonal antibodies between eight to 12 weeks to a greater extent than in the other groups.

Overall, two per cent of those taking propranolol alone had miscarriages, compared to 5 per cent of those taking CGRP monoclonal antibodies.

Current NHS guidance states that patients who are pregnant or trying for a baby should not use the medication.

The class of medication – known as calcitonin gene-related peptide (CGRP) monoclonal antibodies – are injections that have been shown to prevent the condition in 50 per cent of patients

The class of medication – known as calcitonin gene-related peptide (CGRP) monoclonal antibodies – are injections that have been shown to prevent the condition in 50 per cent of patients

However, experts say that the research still raises questions about its use.

‘These results support cautious use of anti-CGRP therapies and emphasize the importance of preconception counseling for women of childbearing potential. 

‘They also highlight the need for future safety research of pregnancy, including studies of fetal and long-term offspring outcomes,’ said study investigator Dr Leah Flatman from the Centre Hospitalier Universitaire Sainte-Justine in Montreal, Quebec, Canada.

Experts say that the problem is how long the drug stays in the system.

Do you want to lose a stone in six weeks?

 

Hi, I’m Emma Bardwell, a nutritionist with more than 15 years’ experience helping people improve their health and lose weight.

I’ve been there. I was overweight, unhappy with my skin and stuck in a rut. Then I changed the way I eat. You can now do the same with my tried-and-tested healthy eating plan. And for DailyMail+ subscribers, it’s completely free. 

Click here to sign up and start your journey

‘When you give CGRP therapies by injection, they stay in the body for 5 months, so this is an issue that could come up with a lot of different patients that are on CGRP therapies where they have an unexpected pregnancy, or maybe they don’t even know that they should be off of therapy for five months before trying to get pregnant,’ says Professor Vincent Martin, director of the Headache and Facial Pain Center at the University of Cincinnati Gardner Neuroscience.

About seven million people in the UK suffer with migraines, with women three times as likely to get them as men, possibly as attacks are linked to the female hormone oestrogen.

The main symptom is an intense, one-sided headache but nausea and increased sensitivity to light and sound are also experienced.

Most patients rely on painkillers to dull the agony, or prescription drugs called triptans which can shorten the length of attacks.

For years, there was nothing that could prevent migraines or reduce their frequency. Then, in March 2020, the NHS gave the green light to calcitonin gene-related peptide (CGRP) monoclonal antibodies to the most severely affected.

The drugs work by blocking a chemical called calcitonin gene related peptide (CGRP), responsible for the pain and nausea associated with migraines – halving the number of attacks.

There are four anti-CGRP drugs approved for use in the UK – erenumab, galcanezumab, fremanezumab and eptinezumab.

When initially approved, experts branded them ‘wonder drugs’ and ‘life changing’ for patients.

Under NHS guidance patients who suffer a migraine on at least four days in a month or more can also get the jab, potentially helping many more every year.

Patients also need to have tried three or more other preventive medicines at the maximum doses they can tolerate for several months each, and they haven’t worked.

You May Also Like

Ladies and Gentlemen…the Northern Lights: Brits stunned after dazzling Aurora Borealis lights up the night sky

The Northern Lights dazzled in the night sky as stargazers across the…

Barack Obama Speaks On Stimulus Checks & Donald Trump

Barack Obama has sparked reactions after he shared a message about stimulus…

Polish Prime Minister Pushed Trump-Russia Collusion Hoax

Polish Prime Minister Donald Tusk is facing a credibility crisis after denying…

Battling Transgenderism Is A Fight Between Institutions And Individuals

The “transgender” obsession of recent history can be removed from society entirely,…